June 21, 2018

MetaStat Presents Positive Data Showing Inhibition of the MENA-pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer

Data presented at the AACR Cancer Dormancy and Residual Disease meeting support a novel therapeutic approach to combating the spread of aggressive cancer

BOSTON--(BUSINESS WIRE)-- MetaStat, Inc. (OTCQB: MTST), a precision medicine company developing novel anti-metastatic medications for patients with aggressive cancer, presented positive results from preclinical studies showing treatment with MAPKAPK2 kinase inhibitors reverse MENA-driven aggressive tumor cell phenotypes and significantly reduce metastasis at the Cancer Dormancy and Residual Disease meeting of the American Association for Cancer Research (AACR) in Montreal, Quebec on June 20, 2018.

“Until recently, the MENA pathway was considered to be an undruggable target. These results show inhibition of the MENA pathway and reversal of MENA-dependent phenotypes are possible by targeting MAPKAPK2,” stated Douglas A. Hamilton, MetaStat’s President and CEO. “We are leveraging a proven and highly successful therapeutic strategy in oncology to develop proprietary first-in-class MAPKAPK2 kinase inhibitors.”

MetaStat reported MENA-induced fibronectin remodeling, tumor cell adhesion and invasion were reversed to MENA-null levels when treated with MAPKAPK2 inhibitors *in vitro*. MAPKAPK2 inhibitor monotherapy reduced lung metastasis similar to the previously published effects of MENA deficiency in the MMTV-PyMT murine model. Significant decreases in the number of animals with any detectable circulating tumor cells (CTCs) following treatment were reported in the MDA-MB-231 human metastatic triple negative breast cancer model. Further, in contrast to paclitaxel monotherapy, treatment with the MAPKAPK2 inhibitor alone or in combination with paclitaxel significantly reduced the growth rate of MMTV-PyMT primary tumors and the development of lung metastasis.

About MetaStat, Inc.

MetaStat is a precision medicine company dedicated to improving the survival of patients with aggressive cancer. Our goal is to transform aggressive cancer into a manageable disease. MetaStat’s therapeutic approach targets the MENA pathway, a critical metastatic pathway responsible for driving tumor resistance and the spread of aggressive cancer. Aggressive cancer that spreads or metastasizes to other parts of the body is responsible for approximately 90% of cancer-related deaths. MetaStat is developing novel inhibitors

targeting the MAPKAPK2 pathway based on the discovery of its role in the activation of the MENA pathway. MetaStat is leveraging a proven and highly successful strategy in oncology through the development of small molecule inhibitors. MetaStat is located in the Innovation and Design Building in Boston’s Seaport District.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Form 10-K and its other filings filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.

View source version on businesswire.com:
https://www.businesswire.com/news/home/20180621005268/en/

MetaStat, Inc.
Daniel Schneiderman, 617-531-0870
VP Finance
dschneiderman@metastat.com

Source: MetaStat, Inc.